GlassScriptPhysician profile
Laurie Grier
NPI 1679595011
$22,678.71
in general payments reported to CMS, 2019-2025
31 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what 85% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $968 · 2021: $1,226 · 2022: $2,227 · 2023: $1,153 · 2024: $1,811 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,717 · Travel and Lodging: $48.69 · Education: $8.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,717.42 |
| Travel and Lodging | $48.69 |
| Education | $8.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $10,530.66 | 2019-2025 | Giapreza, Zevtera, Xacduro |
| Edwards Lifesciences Corporation | $3,409.21 | 2019-2024 | Hemosphere |
| Astrazeneca Pharmaceuticals LP | $1,682.67 | 2019-2025 | Fasenra, Tezspire, Lokelma |
| Actelion Pharmaceuticals US, INC. | $1,410.48 | 2020-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $834.52 | 2019-2025 | Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $714.44 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Glaxosmithkline, LLC. | $613.45 | 2019-2025 | Nucala |
| Janssen Pharmaceuticals, INC | $466.39 | 2019-2024 | Xarelto |
| Insmed, INC. | $432.81 | 2020-2025 | Arikayce, Brinsupri |
| Baxter Healthcare | $351.32 | 2019-2024 | |
| Becton, Dickinson and Company | $324.02 | 2024-2025 | Hemosphere |
| Bard Access Systems, INC. | $300.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $226.74 | 2023-2025 | Glassia |
| Pfizer INC. | $194.30 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $182.71 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $180.45 | 2019-2025 | Ultomiris, Soliris |
| Abiomed | $125.56 | 2022-2024 | Impella |
| Grifols USA, LLC | $124.65 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $99.28 | 2024-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $74.68 | 2022-2023 | |
| Genzyme Corporation | $73.58 | 2025 | |
| Mallinckrodt Hospital Products INC. | $71.11 | 2024-2025 | Terlivaz, Acthar |
| Gilead Sciences, INC. | $70.38 | 2019-2021 | |
| Genentech USA, INC. | $37.60 | 2019-2022 | |
| Shionogi INC | $34.26 | 2020-2021 | |
| Pinnacle Biologics, INC | $27.53 | 2024 | Photofrin |
| Sandoz INC. | $22.19 | 2019 | |
| Resmed Corp | $20.44 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.34 | 2024 | Nuzyra |
| Verona Pharma, INC. | $14.60 | 2025 | Ohtuvayre |
| Shire North American Group INC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Grier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.